AmerisourceBergen, TrakCel debut…

AmerisourceBergen and partner TrakCel rolled out a new platform designed to speed access to prescribed cell and gene therapies to patients.

Dubbed Ocellos, Latin for single eye, the platform is designed to provide visibility throughout a patient’s cell and gene therapy by combining TrakCel’s advanced therapy orchestration platform and AmerisourceBergen’s Fusion system, which is a customer relationship management and support platform offered by the company’s Lash Group.

Ocellos provides a faster and efficient exchange of benefits and eligibility information between hub patient services and providers in order to get patients enrolled in advanced therapies sooner.

“Ensuring that medicines are delivered efficiently and safely to patients is of utmost priority and progressing treatment pathways smoothly and quickly is critical both to successful treatment and to a good patient experience,” Ravi Nalliah, TrakCel’s chief product and strategy officer, said in a statement. “These goals can only be achieved if data is shared securely, accurately and in real-time.”

Ocellas is the most recent collaboration between AmerisourceBergen and TrakCel.

Read more on

Source

Hippo Sighting Report

Help us out, we really appreciate it.

Help contribute to our research, and let us know if you have seen similar situations that we may have missed. Our team will review the details you provide and add to our main list once we verify the information.

stay informed

Subscribe and get the updated Hippo List.

Get notified when we release our updated lists by email.

Make a Donation

Thank you for subscribing!

We will send you an email to confirm your details.  Welcome aboard!

Thanks for sending us your report.

We will review your information, and publish in on our list once we validate the details.